Genentech: Press Releases | Friday, Sep 13, 2024
WEBSep 13, 2024 · Ocrevus Zunovo™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs. South San Francisco, CA -- September 13, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus ...
Roche scores with FDA nod for subcutaneous version of MS star Ocrevus
WEBSep 13, 2024 · Ocrevus is currently Roche’s top-selling product, with 2023 sales reaching 6.38 billion Swiss francs ($7 billion), which was good for 13% growth over 2022 at constant exchange rates.
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze …
WEB6 days ago · ROG.SW. HALO. Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics ...
Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat …
WEB6 days ago · OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional or HCP-administered approximately 10-minute subcutaneous injection approved for both these forms of MS.
New Data for Genentech’s Ocrevus Show That After 10 Years of …
WEBOct 12, 2023 · Ocrevus is the first and only disease-modifying treatment (DMT) in MS to benefit both people with RMS and PPMS and now has 10 years of follow-up data from its three Phase III trials.
ECTRIMS 2023: New under-the-skin Ocrevus found effective in MS
WEBOct 12, 2023 · by Marisa Wexler, MS October 12, 2023. A new under-the-skin formulation of Ocrevus (ocrelizumab) — administered in 10 minutes — is at least as effective as the approved intravenous, or...
FDA approves new drug to treat multiple sclerosis | FDA
WEBOn March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple...
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) …
WEBJul 13, 2023 · Ocrevus is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a …
WEB6 days ago · OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office ... View the performance of global markets and browse news items by region. Equities screener. Find companies based on country, sector, and other equity characteristics.
FDA Approves Ocrevus Zunovo™ | National MS Society
WEBSep 13, 2024 · The U.S. Food and Drug Administration recently approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq, Genentech) as a twice-a-year healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC, under the skin) injectable disease-modifying therapy. This medication is approved for people living with both relapsing ...
Skip to content